(December 20, 2013) Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival… Read on
A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable… Read on
Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro… Read on
A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the… Read on
George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has… Read on
New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer… Read on
Research published in the November 2013 issue of Gynecologic Oncology reports that the use of the chemoresponse assay ChemoFx can lead to improved clinical outcomes for women undergoing treatment for ovarian cancer… Read on
An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971)… Read on
Oregon State University researchers have found that using nanotechnology with heat and cytotoxic drugs can kill up to 95% of ovarian cancer cells… Read on
A new study released in Lancet Oncology showed that abnormal levels of female hormones in the bloodstream may be why women with BRCA1 or BRCA2 mutations are at a higher risk for breast and ovarian cancer and not other cancers… Read on
